MACCHIA, Luigi
 Distribuzione geografica
Continente #
NA - Nord America 5.564
EU - Europa 1.725
AS - Asia 555
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 2
SA - Sud America 1
Totale 7.857
Nazione #
US - Stati Uniti d'America 5.560
CN - Cina 498
SE - Svezia 457
IT - Italia 421
DE - Germania 335
UA - Ucraina 146
GB - Regno Unito 123
FI - Finlandia 77
RU - Federazione Russa 70
FR - Francia 34
BE - Belgio 26
IN - India 24
IE - Irlanda 13
KR - Corea 12
VN - Vietnam 11
EU - Europa 5
PL - Polonia 5
CH - Svizzera 4
ZA - Sudafrica 4
CA - Canada 3
ES - Italia 3
IR - Iran 3
NL - Olanda 3
JP - Giappone 2
AM - Armenia 1
AT - Austria 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BR - Brasile 1
DK - Danimarca 1
GR - Grecia 1
ID - Indonesia 1
IM - Isola di Man 1
LU - Lussemburgo 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UG - Uganda 1
Totale 7.857
Città #
Fairfield 673
Chandler 660
Woodbridge 571
Ashburn 442
Houston 388
Jacksonville 336
Nyköping 309
Seattle 283
Cambridge 254
Wilmington 218
Ann Arbor 210
Beijing 139
Roxbury 135
Lawrence 132
Nanjing 119
New York 117
Des Moines 82
Bari 81
Brooklyn 75
Dearborn 63
Inglewood 46
Shenyang 39
San Diego 38
Redwood City 33
Jiaxing 32
Nanchang 32
Boardman 31
Brussels 24
Changsha 24
Hebei 21
Paris 20
Tianjin 18
Pune 16
Jinan 15
Princeton 14
Dublin 13
Rome 11
Dong Ket 10
Los Angeles 10
Valenzano 10
Milan 9
Modugno 9
Washington 9
Corato 7
Cutrofiano 7
Hefei 7
Zhengzhou 7
Kunming 6
London 6
San Francisco 6
Bitonto 5
Guangzhou 5
Hangzhou 5
Helsinki 5
Martina Franca 5
Taranto 5
Bolzano 4
Forlì 4
Genoa 4
Ningbo 4
Norwalk 4
Salerno 4
West Jordan 4
Amsterdam 3
Auburn Hills 3
Edinburgh 3
Falls Church 3
Foggia 3
Indianapolis 3
Melendugno 3
Montefiore Conca 3
Mumbai 3
Nardò 3
Nürnberg 3
Polignano a Mare 3
Rochester 3
Sannicandro di Bari 3
Taizhou 3
Torino 3
Toronto 3
Triggiano 3
Turi 3
Acquaviva delle Fonti 2
Ardabil 2
Barcelona 2
Bergamo 2
Bollate 2
Bologna 2
Cerignola 2
Chengdu 2
Columbus 2
Coreno Ausonio 2
Cosenza 2
Fuzhou 2
Genova 2
Ginosa 2
Grumo Appula 2
Johannesburg 2
Lecce 2
Lucca 2
Totale 5.968
Nome #
Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects 153
Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study 147
Reazioni ritardate a farmaci: dal test di proliferazione linfocitaria alla desensibilizzazione. 135
Hymenoptera Venom Allergy: Management of children and adults in clinical practice 109
Il fenetil estere dell'acido caffeico è un potente inibitore della via metabolica 5-lipossigenasica -leucotrienica 108
KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection 103
A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy 103
null 101
Indirect food contact in severe fish allergy 100
Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review 100
Pollini e pollinosi in Puglia. La notte dei Ricercatori. Bari, 23 settembre 2011 99
5-lipoxygenase upregulation by dexamethasone in human mast cells 91
Monitoring of atmospheric conditions and forecast of olive pollen season. 84
Allergy to artichoke: a case report 84
Arachidonic acid metabolism in the human mast cell line HMC-1. 5-lipoxygenase gene expression and biosynthesis of thromboxane 84
Is immunotherapy with fungal vaccines effective? 83
Beauvericin: chemistry, biology and significance 82
Wasp immunotherapy induced long-term and IgG4-independent protection 82
Fig and mulberry cross-allergy 81
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 79
Purification and fine characterization of the major allergen from Olea europaea pollen extract 78
Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast 78
Test di proliferazione linfocitaria nella diagnosi delle reazioni ritardate a farmaci 78
Allergy to pomegranate and artichoke, novel food allergens of the Mediterranean Diet 76
Should succinate esters be considered excipients in systemic corticosteroid allergy? 76
Allergeni alimentari emergenti della Dieta Mediterranea. 75
null 74
Cost-effectiveness of grass pollen allergen immunotherapy in adults 74
null 74
Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study 74
Second generation antihistamines in the treatment of seasonal allergic rhinitis due to Parietaria and cypress pollen 72
L'allergia alimentare della Dieta Mediterranea 72
null 71
null 71
A HPTLC approach to quantitative determination of some prostaglandins in serum: study in normal and asthmatic subjects 70
null 70
null 68
null 68
Sviluppo ed applicazione di un protocollo di desensibilizzazione rapida per Rituximab. 67
Expression of prostaglandin endoperoxide H synthase 1 and 2 in human placenta at term 66
Studi su Omalizumab nella terapia dell'asma severo. Valutazione degli effetti sulla risposta immunologica IgE in vivo. Valutazione della tollerabilità. 66
Allergia al latte. Studio sulla risposta IgE-mediata in vivo verso frazioni proteiche di latte di capra Garganica 66
null 65
null 65
La Notte dei Ricercatori - 23 settembre 2011 - Piazza del Ferrarese - Bari 64
Omalizumab in long-term treatment of refractory chronic spontaneus urticaria:effects of discontinuation 64
null 64
null 64
Vicia faba hypersensitivity and ASA intolerance in a farmer: A case report 63
Cytotoxic effects of the mycotoxin beauvericin to human cell lines of myeloid origin 63
Italian real-life experience of omalizumab 62
Metodo diagnostico ELISA applicabile all'allergia respiratoria da polline di Cupressus arizonica 60
Zucchini allergy: a case report 60
Retrospective monitoring in the management of persistent asthma 60
null 60
General adverse reaction to aspirin administered by transdermal iontophoresis 58
null 58
Terapia dell'asma severo con omalizumab: uno studio real life in 51 pazienti. 57
null 57
Desensitization in Iron Product Allergy 57
Idiopathic nonhistaminergic angioedema: A single-center real-life experience from Italy 56
A new subcutaneous protocol for persistent desensitization to Rituximab 55
Allergens of Arizona cypress (Cupressus arizonica) pollen: characterization of the pollen extract and identification of the allergenic components 54
Omalizumab nel trattamento dell'allergia alimentare 54
null 54
Association between γ marker, human leucocyte antigens and killer immunoglobulin-like receptors and the natural course of human cytomegalovirus infection: a pilot study performed in a Sicilian population 53
Olive pollen allergy in Bari, Italy 52
Allergy to mint (Mentha spicata) 52
Cyclooxygenase-2 expression in oral squamous cell carcinoma 52
Omalizumab in severe allergic asthma: efficacy assessment by comparison of symptom score and peak expiratory flow values before and after therapy 51
Allergia alimentare a Leguminose della dieta mediterranea: Phaseoulus vulgaris (fagiolo) e Pisum Sativum (pisello) 51
Beauvericin cytotoxicity to the invertebrate cell line SF-9 51
Immunological and non-immunological mechanisms of allergic diseases in the elderly: Biological and clinical characteristics 51
Omalizumab For The Treatment of Persistent Drug Induced Urticaria Elicited By Thienopyridines: A Case Report 50
null 50
Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases 49
Leukotriene biosynthesis inhibition and direct 5-lipoxygenase (5-LO) non competitive inhibition by the Cys-LT1 receptor antagonists montelukast 49
Rapid desensitization to Rituximab 48
null 48
Biosensori cellulari nella valutazione di nuovi detergenti ecosostenibili 47
Due anni di terapia con Omalizumab: valutazione di efficacia e tollerabilità in 10 pazienti con asma severo non controllato 46
Novel inhibitory effect on 5-lipoxygenase by the anti-asthma drug montelukast 45
Apoptosis induced by the Fusarium mycotoxin beauvericin in mammalian cells 45
Immunological characterization of onion (Allium cepa) allergy 45
Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2-year real-life study 43
High levels of gut-homing immunoglobulin A-positive+B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients 43
High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients 43
L'orticaria (da un punto di vista allergologico) 42
Airborne Cupressaceae pollen in Southern Italy 42
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 42
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 41
Studio del pH e dei markers di stress ossidativi nel condensato di pazienti con fibrosi cistica. 40
Multicenter double-blind comparative study of terfenadine and cetirizine in hay fever 40
Toxicity assessment of fungal biocontrol agents using two different (Artemia salina and Daphnia magna) invertebrate bioassays 40
IgE-mediated reaction induced by arugula (Eruca sativa) ingestion compared with a spectrum of Brassicaeae proteins 40
Omalizumab nell'orticaria cronica spontanea: uno studio real-life su 14 pazienti 40
Inibizione della via metabolica 5-lipossigenasica/leucotrienica da parte di sostanze antiossidanti di origine naturale. 40
Fennel (Foeniculum vulgare) allergy. 40
Studio dell'inquinamento atmosferico nell' area urbana di Bari per l' anno 1981 39
Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: Data from a real-life cohort 39
Totale 6.555
Categoria #
all - tutte 31.314
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.314


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019427 0 0 0 0 0 0 0 0 0 0 181 246
2019/20201.976 309 90 82 167 162 175 205 149 193 139 232 73
2020/20211.236 118 99 107 72 144 105 122 103 101 136 70 59
2021/20221.089 30 100 42 41 67 120 25 67 52 78 181 286
2022/20231.587 186 250 122 118 176 203 26 151 282 6 40 27
2023/2024677 58 114 35 39 47 237 44 43 27 32 1 0
Totale 8.107